{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:32:45Z","timestamp":1760149965342,"version":"build-2065373602"},"reference-count":60,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["20173MFDS171"],"award-info":[{"award-number":["20173MFDS171"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background: Empagliflozin has been shown to reduce cardiovascular morbidity and mortality in patients with type 2 diabetes. Various research on its efficacy in patients with chronic kidney disease (CKD) have been actively conducted. So far, few studies have investigated the safety of these adverse effects specifically in Asians with CKD. We aim to address these safety concerns on a patient population of Asian CKD patients using real-world data. Methods: We conducted a retrospective cohort study using health insurance data from the Korean Health Insurance Review &amp; Assessment Service and compared safety outcomes between empagliflozin and sitagliptin in 26,347 CKD patients diagnosed with diabetes. Adverse outcomes, including major adverse cardiac events (MACEs), all-cause mortality, myocardial infarction (MI), stroke, and hospitalization for heart failure (HHF), among others, were assessed. Results: Among a 1:1 matched cohort (6170 on empagliflozin, 6170 on sitagliptin), empagliflozin was associated with a significant reduction in MACEs, all-cause mortality, MI, hospitalization for unstable angina, coronary revascularization, HHF, hypoglycemic events, and urinary tract infections, but increased the risk of genital tract infections. No significant changes were observed for transient ischemic attack, acute kidney injury, volume depletion, diabetic ketoacidosis, thromboembolic events, and fractures. Conclusions: The usage of empagliflozin in diabetic CKD patients shows a significant reduction in many adverse outcomes compared to sitagliptin, but with an increased risk of genital tract infections. These findings provide evidence for future clinical decision-making around the use of empagliflozin in Asian CKD patients.<\/jats:p>","DOI":"10.3390\/pharmaceutics15102394","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T01:42:12Z","timestamp":1695865332000},"page":"2394","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Safety Analysis of Empagliflozin in Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease versus Normal Kidney Function: A Nationwide Cohort Study in Korea"],"prefix":"10.3390","volume":"15","author":[{"given":"Ha Young","family":"Jang","sequence":"first","affiliation":[{"name":"College of Pharmacy, Gachon University, Incheon 21936, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4976-3343","authenticated-orcid":false,"given":"In-Wha","family":"Kim","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Mi","family":"Oh","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/cd17-0119","article-title":"Standards of Medical Care in Diabetes-2018 Abridged for Primary Care Providers","volume":"36","year":"2018","journal-title":"Clin. Diabetes"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1016\/j.jacc.2018.09.020","article-title":"2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways","volume":"72","author":"Das","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","unstructured":"DailyMed (2023, June 01). Drug Label: Empagliflozin (JARDIANCE), Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical Manifestations of Kidney Disease Among US Adults with Diabetes, 1988\u20132014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2337\/dc21-2034","article-title":"Safety of Empagliflozin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials","volume":"45","author":"Tuttle","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1007\/s13300-020-00930-x","article-title":"SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes","volume":"11","author":"Wheeler","year":"2020","journal-title":"Diabetes Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"267","DOI":"10.14740\/jocmr3761","article-title":"Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center","volume":"11","author":"Sugiyama","year":"2019","journal-title":"J. Clin. Med. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e2237606","DOI":"10.1001\/jamanetworkopen.2022.37606","article-title":"Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics","volume":"5","author":"Htoo","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/1753-0407.13261","article-title":"Effects of SGLT2 inhibitors on patients with diabetic kidney disease: A preliminary study on the basis of podocyturia","volume":"14","author":"Durcan","year":"2022","journal-title":"J. Diabetes"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.atherosclerosis.2015.07.033","article-title":"The ACC\/AHA 2013 pooled cohort equations compared to a Korean Risk Prediction Model for atherosclerotic cardiovascular disease","volume":"242","author":"Jung","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"R99","DOI":"10.1530\/EJE-13-0307","article-title":"Pathogenesis of type 2 diabetes in South Asians","volume":"169","author":"Bakker","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s11892-015-0602-9","article-title":"beta cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians","volume":"15","author":"Yabe","year":"2015","journal-title":"Curr. Diabetes Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Zheng","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S2213-8587(14)70137-8","article-title":"Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): A cross-sectional study of a prospective cohort","volume":"2","author":"Yeung","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2337\/dc08-1908","article-title":"Effects of structured versus usual care on renal endpoint in type 2 diabetes: The SURE study: A randomized multicenter translational study","volume":"32","author":"Chan","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/nyas.12098","article-title":"Type 2 diabetes in East Asians: Similarities and differences with populations in Europe and the United States","volume":"1281","author":"Ma","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s11886-014-0476-5","article-title":"Diabetes and associated complications in the South Asian population","volume":"16","author":"Shah","year":"2014","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_23","unstructured":"Food-and-Drug-Administration-(FDA) (2018). Framework for FDA\u2019s Real-World Evidence Program."},{"key":"ref_24","unstructured":"Food-and-Drug-Administration-(FDA) (2021, September 24). Submitting Documents Utilizing Real-World Data and Real-World Evidence to FDA for Drugs and Biologics, Available online: https:\/\/www.fda.gov\/media\/124795\/download."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","article-title":"Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data","volume":"32","author":"Kim","year":"2017","journal-title":"J. Korean Med. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies","volume":"12","author":"Altman","year":"2014","journal-title":"Int. J. Surg."},{"key":"ref_27","unstructured":"Food-and-Drug-Administration-(FDA) (2013). Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data, Guidance for Industry and FDA Staff."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/dom.13297","article-title":"Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study","volume":"20","author":"Kim","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7326\/M20-0289","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis: A Multicenter Cohort Study","volume":"173","author":"Douros","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12933-020-01118-0","article-title":"Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor","volume":"19","author":"Lee","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12933-020-01060-1","article-title":"Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: A nationwide population-based cohort study","volume":"19","author":"Seong","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/dom.14261","article-title":"Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study","volume":"23","author":"Han","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_34","unstructured":"Parsons, L.S. (2017, January 01). Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques. Available online: http:\/\/www2.sas.com\/proceedings\/sugi26\/p214-26.pdf."},{"key":"ref_35","unstructured":"NCSS-Statistical-Software (2017, July 01). Data Matching\u2014Optimal and Greedy. Available online: http:\/\/ncss.wpengine.netdna-cdn.com\/wp-content\/themes\/ncss\/pdf\/Procedures\/NCSS\/Data_Matching-Optimal_and_Greedy.pdf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","article-title":"Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: Therapeutic implications","volume":"27","author":"Gerich","year":"2010","journal-title":"Diabet. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"F889","DOI":"10.1152\/ajprenal.00267.2015","article-title":"Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus","volume":"309","author":"Norton","year":"2015","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.2337\/dc18-0394","article-title":"Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth with Type 2 Diabetes","volume":"41","author":"Bjornstad","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1681\/ASN.V10122569","article-title":"Glomerular hyperfiltration in experimental diabetes mellitus: Potential role of tubular reabsorption","volume":"10","author":"Vallon","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1093\/ndt\/16.7.1382","article-title":"Urinary albumin excretion rate and glomerular filtration rate in the prediction of diabetic nephropathy; a long-term follow-up study of childhood onset type-1 diabetic patients","volume":"16","author":"Dahlquist","year":"2001","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4158\/EP.14.6.782","article-title":"Inhibition of renal glucose reabsorption: A novel strategy for achieving glucose control in type 2 diabetes mellitus","volume":"14","author":"DeFronzo","year":"2008","journal-title":"Endocr. Pract."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1479164115616901","article-title":"Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus","volume":"13","author":"Neeland","year":"2016","journal-title":"Diab Vasc. Dis. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12933-018-0750-8","article-title":"Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury","volume":"17","author":"Aroor","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Lee, W.C., Chau, Y.Y., Ng, H.Y., Chen, C.H., Wang, P.W., Liou, C.W., Lin, T.K., and Chen, J.B. (2019). Empagliflozin Protects HK-2 Cells from High Glucose-Mediated Injuries via a Mitochondrial Mechanism. Cells, 8.","DOI":"10.3390\/cells8091085"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.2147\/DMSO.S243170","article-title":"Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha","volume":"13","author":"Ndibalema","year":"2020","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/ckj\/sfac044","article-title":"A real-world study on SGLT2 inhibitors and diabetic kidney disease progression","volume":"15","author":"Liu","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2337\/diacare.27.4.874","article-title":"Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study","volume":"27","author":"Chan","year":"2004","journal-title":"Diabetes Care"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1161\/HYPERTENSIONAHA.113.02989","article-title":"Racial differences in sensitivity of blood pressure to aldosterone","volume":"63","author":"Tu","year":"2014","journal-title":"Hypertension"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/jdi.12971","article-title":"Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME((R)) trial","volume":"10","author":"Kadowaki","year":"2019","journal-title":"J. Diabetes Investig."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.clinthera.2014.08.001","article-title":"Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus","volume":"36","author":"Sarashina","year":"2014","journal-title":"Clin. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/dom.12182","article-title":"Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment","volume":"16","author":"Macha","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"928121","DOI":"10.3389\/fphar.2022.928121","article-title":"Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data","volume":"13","author":"Jang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/dom.13532","article-title":"Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis","volume":"21","author":"Cahn","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): A multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/dom.14239","article-title":"Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea)","volume":"23","author":"Koh","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/dc17-1011","article-title":"Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis","volume":"40","author":"Nadkarni","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/dom.13176","article-title":"Initiation of dapagliflozin and treatment-emergent fractures","volume":"20","author":"Toulis","year":"2018","journal-title":"Diabetes Obes. Metab."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/10\/2394\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:59:59Z","timestamp":1760129999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/10\/2394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":60,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["pharmaceutics15102394"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15102394","relation":{},"ISSN":["1999-4923"],"issn-type":[{"type":"electronic","value":"1999-4923"}],"subject":[],"published":{"date-parts":[[2023,9,27]]}}}